Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD37.

× No keyword cloud information.

6 in total

1. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Authors: Xiaobin Zhao; Rosa Lapalombella; Trupti Joshi; Carolyn Cheney; Aruna Gowda; Martha S Hayden-Ledbetter; Peter R Baum; Thomas S Lin; David Jarjoura; Amy Lehman; Donna Kussewitt; Robert J Lee; Michael A Caligiuri; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal: Blood Date: 2007-04-17 Impact factor: 22.113

2. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.

Authors: Bo Yu; Yicheng Mao; Yuan Yuan; Chaofang Yue; Xinmei Wang; Xiaokui Mo; David Jarjoura; Michael E Paulaitis; Robert J Lee; John C Byrd; L James Lee; Natarajan Muthusamy
Journal: Biomaterials Date: 2013-05-28 Impact factor: 12.479

3. 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.

Authors: Ada H V Repetto-Llamazares; Roy H Larsen; Anna Maria Giusti; Elena Riccardi; Øyvind S Bruland; Pål Kristian Selbo; Jostein Dahle
Journal: PLoS One Date: 2014-07-28 Impact factor: 3.240

4. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Authors: Ada H V Repetto-Llamazares; Roy H Larsen; Sebastian Patzke; Karianne G Fleten; David Didierlaurent; Alexandre Pichard; Jean Pierre Pouget; Jostein Dahle
Journal: PLoS One Date: 2015-06-11 Impact factor: 3.240

5. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.

Authors: Ada H V Repetto-Llamazares; Roy H Larsen; Camilla Mollatt; Michael Lassmann; Jostein Dahle
Journal: Curr Radiopharm Date: 2013-03

6. Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.

Authors: Caroline Stokke; Johan Blakkisrud; Ayca Løndalen; Jostein Dahle; Anne C T Martinsen; Harald Holte; Arne Kolstad
Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-22 Impact factor: 9.236